Sugi Predict

Sugi Predict / Compounds / SCHEMBL991320

SCHEMBL991320

SCHEMBL991320

COC(=O)c1cnc(CO)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 4/20 0.49
▸ KDM4E B2RXH2 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ SIRT6 Q8N6T7 1/20 0.41
▸ LCK P06239 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ PCSK9 Q8NBP7 1/20 0.38
▸ GABRP O00591 2/20 0.38
▸ GABRD O14764 2/20 0.38
▸ GABRA1 P14867 2/20 0.38
▸ GABRB1 P18505 2/20 0.38
▸ GABRG2 P18507 2/20 0.38
▸ GABRB3 P28472 2/20 0.38
▸ GABRA5 P31644 2/20 0.38
▸ GABRA3 P34903 2/20 0.38
▸ GABRA2 P47869 2/20 0.38
▸ GABRB2 P47870 2/20 0.38
▸ GABRA4 P48169 2/20 0.38
▸ GABRE P78334 2/20 0.38
▸ GABRA6 Q16445 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3510508 0.86 MAPK1 (0.46) MAPK1KDM4EL3MBTL1SIRT6LCK
SCHEMBL12844583 0.85 MAPK1 (0.49) MAPK1KDM4EL3MBTL1SIRT6LCK
SCHEMBL68869 0.84 MAPK1 (0.63) MAPK1KDM4EL3MBTL1SIRT6LCK
SCHEMBL31390521 0.84 MAPK1 (0.47) MAPK1KDM4EL3MBTL1SIRT6LCK
SCHEMBL31390501 0.84 MAPK1 (0.47) MAPK1KDM4EL3MBTL1SIRT6LCK
SCHEMBL480161 0.84 MAPK1 (0.47) MAPK1KDM4EL3MBTL1SIRT6LCK
SCHEMBL11030074 0.84 MAPK1 (0.47) MAPK1KDM4EL3MBTL1SIRT6LCK
SCHEMBL16615936 0.84 MAPK1 (0.47) MAPK1KDM4EL3MBTL1SIRT6LCK
SCHEMBL6917612 0.84 MAPK1 (0.47) MAPK1KDM4EL3MBTL1SIRT6LCK
Hydrochloric Acid SCHEMBL1566955 0.82 MAPK1 (0.46) MAPK1KDM4EL3MBTL1SIRT6LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250312504-A1 VOLATILE COMPOSITION DISPENSER FOR COMPOSITIONS COMPRISING A META-(C1-C4 ALKOXY) SALICYLALDEHYDE THE PROCTER & GAMBLE COMPANY 2025-10-09 — — US disclosed
US-20240199997-A1 COMPOSITIONS COMPRISING A META-(C1-C4 ALKOXY) SALICYLALDEHYDE PROCTER & GAMBLE COMPANY, THE 2024-06-20 — — US disclosed
US-11661397-B2 1,4-disubstituted imidazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-05-30 — — US disclosed
US-11661397-B2 1,4-disubstituted imidazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-05-30 — — US disclosed
US-11434472-B2 Agent for removing undifferentiated iPS cells Sumitomo Pharma Co., Ltd. (JP) 2022-09-06 — — US disclosed
US-11434472-B2 Agent for removing undifferentiated iPS cells Sumitomo Pharma Co., Ltd. (JP) 2022-09-06 — — US disclosed
WO-2022011211-A1 DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2022-01-13 — — WO disclosed
EP-3668869-B1 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE DERIVATIVES AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AS IMMUNOSTIMULANTS BRISTOL MYERS SQUIBB CO (US) 2022-01-12 — — EP disclosed
US-20210171440-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2021-06-10 — — US disclosed
US-20210171440-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2021-06-10 — — US disclosed
US-20120202804-A1 FUSED AMINODIHYDRO-OXAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-08-09 — — US disclosed
US-20120202804-A1 FUSED AMINODIHYDRO-OXAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-08-09 — — US disclosed
WO-2012098213-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-07-26 — — WO disclosed
WO-2012098213-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-07-26 — — WO disclosed
US-20120190672-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-07-26 — — US disclosed
US-20120190672-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-07-26 — — US disclosed
US-20120190672-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-07-26 — — US disclosed
EP-2456774-A1 FUSED AMINODIHYDRO-OXAZINE DERIVATIVES Eisai R&D Management Co., Ltd. (JP) 2012-05-30 — — EP disclosed
WO-2011009898-A1 FUSED AMINODIHYDRO-OXAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD (JP) 2011-01-27 — — WO disclosed
WO-2011009898-A1 FUSED AMINODIHYDRO-OXAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD (JP) 2011-01-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190672-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES BACE1, APP, BACE2 MAPK1 2367/4885KDM4E 655/4885L3MBTL1 1721/4885
US-20120202804-A1 FUSED AMINODIHYDRO-OXAZINE DERIVATIVES BACE1, APP, BACE2 MAPK1 1553/4885KDM4E 1400/4885L3MBTL1 417/4885
US-11434472-B2 Agent for removing undifferentiated iPS cells SALL4, NR4A2, NES MAPK1 2722/4885KDM4E 304/4885L3MBTL1 2678/4885
US-20210171440-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE NR4A3, NR0B1, NR2C2 MAPK1 2980/4885KDM4E 1942/4885L3MBTL1 3296/4885
US-11661397-B2 1,4-disubstituted imidazole derivative NR4A3, NR0B1, NR2C2 MAPK1 2980/4885KDM4E 1942/4885L3MBTL1 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.